Core Viewpoint - E.F. Hutton & Co. acted as the exclusive placement agent for Shuttle Pharmaceuticals' $3.5 million public offering, aimed at supporting the company's AI-driven platform for molecular discovery and drug development [1][2]. Group 1: Offering Details - Shuttle Pharmaceuticals entered into a securities purchase agreement for the issuance of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares, resulting in gross proceeds of approximately $3.5 million before fees and expenses [2]. - The offering closed on March 10, 2026, with Shuttle Pharmaceuticals planning to allocate up to $1.5 million of the net proceeds for marketing efforts, while the remainder will be used for working capital and general corporate purposes [3]. Group 2: Company and Executive Commentary - Joseph T. Rallo, CEO of E.F. Hutton & Co., expressed satisfaction in supporting Shuttle Pharmaceuticals, highlighting the transaction's alignment with the company's operational priorities and development objectives [4]. - The securities were offered under a registration statement filed with the SEC on February 11, 2026, which became effective on February 17, 2026, and the offering was conducted via a prospectus that is part of this registration statement [4]. Group 3: Company Background - E.F. Hutton & Co. is an investment bank and broker-dealer based in Manhattan, providing a range of advisory and financing solutions to various clients, including corporates and public-private partnerships [6]. - The firm offers comprehensive investment banking services, including capital markets, PIPEs, private placements, M&A advisory, and strategic financing, with a global presence across multiple regions [6].

Core Viewpoint - A securities fraud class action lawsuit has been initiated against Aquestive Therapeutics, Inc. for alleged misrepresentations regarding its New Drug Application for Anaphylm (Dibutepinephrine) sublingual film, affecting investors who purchased securities between June 16, 2025, and January 8, 2026 [5][6]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey on behalf of investors who acquired Aquestive securities during the specified period [5]. - The allegations include violations of the Securities Exchange Act of 1934 against the Company and certain senior officers [5]. Group 2: Investor Actions - Investors who purchased or acquired Aquestive securities are encouraged to discuss their legal rights and options, with a deadline to file as lead plaintiff by May 4, 2026 [3][4]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its inception in 1993 and has a strong track record in class action litigation [7].

Core Insights - Bavarian Nordic has entered into a manufacturing agreement with Serum Institute of India (SII) to enhance the production capacity of its chikungunya vaccine (CHIKV VLP) for low- and middle-income countries [1][2] - The new agreement builds on an existing partnership for the mpox vaccine and replaces a previous deal with Biological E, with both companies exploring co-development opportunities [2][3] Vaccine Details - The CHIKV VLP vaccine is a prefilled, single-dose, adjuvanted virus-like particle recombinant protein product intended for immunization against chikungunya virus in individuals aged 12 and above [3][4] - The vaccine is designed to elicit a strong seroresponse, with protective immunity developing within one week post-vaccination, and is non-infectious due to the absence of viral genetic material [4] Regulatory and Market Developments - The CHIKV VLP vaccine, marketed as Vimkunya, has received approvals from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), the European Commission, and the US FDA in 2025 [4] - Regulatory reviews are currently ongoing in Canada and Switzerland, with the vaccine launched in the UK in September 2025 following a 170% increase in travel-related chikungunya cases reported in August 2025 compared to the same month in 2024 [5]

Core Viewpoint - SciSparc Ltd. has announced an advancement in its collaboration with NeuroThera Labs Inc. for a novel combination therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD) [1] Group 1: Company Overview - SciSparc Ltd. holds a controlling interest of approximately 75% in NeuroThera Labs Inc., which focuses on developing treatments for central nervous system disorders [1] - SciSparc is engaged in clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals, with ongoing drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [4] Group 2: Collaboration and Patent Development - NeuroThera Labs has published an international patent application for a combination therapy involving 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) [2] - The combination therapy aims to address obesity and MASLD, which affects over 890 million adults and approximately 30% of the global adult population, respectively [2] Group 3: Market Potential - The global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronic disease [3] - The MEAI-PEA combination is expected to provide a safer and more cost-effective alternative to GLP-1 agonists for treating obesity and MASLD [2][3]

Core Insights - Helus Pharma has appointed Jill Conwell as Chief People Officer, effective immediately, to support the company's growth and clinical programs [1][3][9] Company Overview - Helus Pharma is a clinical stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) aimed at addressing mental health conditions such as depression and anxiety [5][6] - The company is currently advancing its clinical pipeline, including HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder [6] Leadership Experience - Jill Conwell brings over 20 years of leadership experience in the life sciences sector, with a strong background in organizational strategy, talent development, and corporate communications [2][4] - Conwell has held senior roles at Aclaris Therapeutics, Idera Pharmaceuticals, and Shire Pharmaceuticals, contributing to organizational growth and transformation [3][4] Strategic Goals - The appointment of Conwell is expected to enhance Helus Pharma's ability to attract top talent and foster a collaborative culture as the company prepares for its next growth phase [3][4] - Conwell expressed enthusiasm about joining Helus Pharma at a critical time, emphasizing the company's innovative approach to mental health treatment [4]

MONTREAL, March 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2025 financial results on Thursday, March 19, 2026 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, March 19, 2026Time: 8:30 a.m. ETTelephone: Toll Free: 1-888-699-1199 o ...

Company Performance - Pfizer (PFE) has shown strong performance in 2026, with a year-to-date increase of 9.64% [1] - The current dividend yield for PFE is 6.42%, making it attractive for income investors [2] Covered Call Strategy - A covered call strategy can generate additional income from high-yielding stocks like PFE [2] - Buying 100 shares of PFE costs approximately $2,723, with a May 15, $30 strike call option trading at around $0.24, generating $24 in premium per contract [3] - Selling the May $30 strike call option can yield an income of 0.9% over 65 days, equating to an annualized return of about 10.9% [4] - If PFE closes above $30 at expiration, the total return could reach 10.9%, which annualizes to 61.0% [4] Alternative Covered Call Example - An alternative covered call using the December 18, $30 strike option can generate an income of 5.2% over 282 days, translating to an annualized return of approximately 6.7% [5] - If PFE closes above $30 at expiration, the total return could be 15.6%, which annualizes to 20.2% [5] Technical Opinion - The Barchart Technical Opinion rates PFE as a 100% Buy, indicating a strong short-term outlook for maintaining the current direction [7] - Long-term indicators support a continuation of the trend, with implied volatility at 25.34%, compared to a 12-month low of 18.25% and a high of 52.17% [7] Company Overview - Pfizer Inc. is a research-based, global biopharmaceutical company with a sustainable pipeline and multiple late-stage programs that can drive growth [8]

Core Insights - CervoMed is advancing its drug candidate neflamapimod for treating dementia with Lewy bodies (DLB), a condition with no approved treatments in the US or EU [1][6] - The company plans to initiate a Phase 3 trial in DLB patients, specifically targeting those without Alzheimer's disease co-pathology, in the second half of 2026 [6] Group 1: Clinical Trial Results - In the Phase 2b RewinD-LB trial, neflamapimod showed a statistically significant and clinically meaningful slowing of clinical progression in DLB patients without Alzheimer's disease co-pathology [2] - Secondary analyses will present new outcomes based on pre-specified plasma pTau181 levels, supporting the planned Phase 3 trial's patient selection criteria [2] Group 2: Upcoming Presentations - CervoMed will present findings at the AD/PD 2026 conference in Copenhagen, including an oral presentation on neflamapimod's treatment effects in DLB patients [5] - A scientific symposium sponsored by CervoMed will discuss advances in DLB research and new drug development strategies, featuring presentations from leading researchers [4] Group 3: Drug Development Strategy - Neflamapimod targets critical disease processes in neuroinflammation and neurodegeneration, aiming to inhibit a key enzyme involved in these processes [6] - The company is focusing on understanding the dose-response relationship of neflamapimod through new pharmacokinetic and pharmacodynamic analyses from the RewinD-LB trial [4]

Core Insights - Tilray Pharma has formed a strategic partnership with Tilray Medical, CC Pharma, and "gesund leben" cooperation to enhance its market presence in Germany [1][2][4] - The partnership aims to provide a comprehensive range of healthcare solutions, including prescription medications and medical cannabis, to pharmacies across Germany [2][5] Group 1: Partnership Details - The collaboration will take effect on April 1, 2026, focusing on improving pharmacy access and product availability [2] - The "gesund leben" cooperation includes approximately 3,600 member pharmacies, offering benefits such as digital access and competitive purchasing terms [3][8] - This partnership allows CC Pharma to access over 20% of German pharmacies, significantly expanding its market reach [4] Group 2: Market Context - Germany is identified as a crucial and dynamic healthcare market in Europe, making this partnership strategically significant for Tilray [4] - The alliance is expected to enhance service offerings and operational efficiency for pharmacies, thereby increasing customer traffic and sales [3][8] Group 3: Company Background - CC Pharma is a leading pharmaceutical distributor in Germany, serving over 16,000 pharmacies with a wide range of medicines [4][9] - Tilray Medical specializes in providing medical cannabis and has established itself as a significant supplier in the European market [10]

Core Viewpoint - Indivior Pharmaceuticals, Inc. plans to offer $400 million in convertible senior notes due 2031, with an additional $60 million option for initial purchasers, aimed at qualified institutional buyers [1][6]. Group 1: Offering Details - The notes will be senior, unsecured obligations, accruing interest payable semi-annually, maturing on March 15, 2031, with conversion rights for noteholders under specific conditions [2]. - The notes can be redeemed by Indivior starting March 20, 2029, if certain stock price conditions are met, with a redemption price equal to the principal plus accrued interest [3]. Group 2: Use of Proceeds - Approximately $239 million of the net proceeds will be used to repay borrowings and terminate the note purchase agreement related to the term loan and revolving credit facility [4]. - Up to $75 million will be allocated for repurchasing common stock from certain purchasers of the notes, with the remainder for general corporate purposes [4]. Group 3: Market Impact - The concurrent stock repurchases could influence the market price of Indivior's common stock, potentially leading to a higher effective conversion price for the notes [5]. Group 4: Company Background - Indivior is a leader in long-acting injectable treatments for opioid use disorder, focusing on evidence-based treatment and advancing understanding of opioid use disorder as a chronic but treatable condition [7].